BioCentury | Feb 26, 2021
Management Tracks

Ziopharm CEO stepping down; plus moves at ChemoCentryx, ReForm, Monte Rosa and Enterin

...strategy to convert hospital-based intravenous dosing to subcutaneous injections on an outpatient basis.Protein degradation play Monte Rosa Therapeutics Inc....
...including KLW Advisors, Ondra Partners, HSBC Securities, SG Cowen and Bear Sterns. BC Staff Ziopharm Oncology Inc. ChemoCentryx Inc. Monte Rosa Therapeutics Inc. Enterin...
BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

...launched since 2018.Three —Amphista Therapeutics Ltd., Monte Rosa Therapeutics Inc....
BioCentury | Nov 5, 2020
Management Tracks

Rosén joins Horizon as CSO and R&D head; plus moves at Boehringer, Dr. Reddy’s, Mylan and more

...effective Nov. 9. Chien was chief commercial officer at Krystal Biotech Inc. (NASDAQ:KRYS).Protein degradation newco Monte Rosa Therapeutics Inc....
...Bio Inc. (NASDAQ:GOSS). Danielle Golovin Boehringer Ingelheim Horizon Therapeutics plc GlaxoSmithKline plc Dr. Reddy's Laboratories Ltd. Mylan N.V. Rhythm Pharmaceuticals Inc. Silence Therapeutics plc Monte Rosa Therapeutics Inc. Relmada...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...as Bristol-Myers Squibb Co. (NYSE:BMY), C4 and Monte Rosa Therapeutics Inc....
...Inc. PolyProx Therapeutics Ltd. Cedilla Therapeutics Inc. Cullgen Inc. Frontier Medicines Corp. Monte Rosa Therapeutics Inc. Ranok...
BioCentury | Sep 25, 2020
Finance

Sept. 24 Quick Takes: AveXis vets steer Taysha to IPO; plus Exact Sciences, Monte Rosa, OBiO, Moderna, Immetas and more

...cap of more than $14 billion.Aisling leads $96M series B for Monte RosaProtein degradation company Monte Rosa Therapeutics Inc....
BioCentury | May 27, 2020
Emerging Company Profile

Versant’s Monte Rosa debuts with $32.5M, library of molecular glues for protein degradation

...by the field’s first drugs, thalidomide derivatives. Launched from Versant Ventures’ Swiss incubator lab Ridgeline, Monte Rosa Therapeutics Inc....
...degrons is ongoing at BMS following the pharma’s acquisition of Celgene in 2019. COMPANY PROFILE Monte Rosa Therapeutics Inc....
...Cereblon IKAROS (IKZF1; LYF1) - IKAROS family zinc finger 1 Karen Tkach Tuzman, Associate Editor protein degradation Monte Rosa Therapeutics Inc....
BioCentury | Feb 8, 2020
Tools & Techniques

Beyond PROTACs and the proteasome: broadening the TAC toolbox

...its chemoproteomics platform to find ligands to incorporate into targeted protein degraders, and stealth company Monte Rosa Therapeutics Inc....
Items per page:
1 - 7 of 7
BioCentury | Feb 26, 2021
Management Tracks

Ziopharm CEO stepping down; plus moves at ChemoCentryx, ReForm, Monte Rosa and Enterin

...strategy to convert hospital-based intravenous dosing to subcutaneous injections on an outpatient basis.Protein degradation play Monte Rosa Therapeutics Inc....
...including KLW Advisors, Ondra Partners, HSBC Securities, SG Cowen and Bear Sterns. BC Staff Ziopharm Oncology Inc. ChemoCentryx Inc. Monte Rosa Therapeutics Inc. Enterin...
BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

...launched since 2018.Three —Amphista Therapeutics Ltd., Monte Rosa Therapeutics Inc....
BioCentury | Nov 5, 2020
Management Tracks

Rosén joins Horizon as CSO and R&D head; plus moves at Boehringer, Dr. Reddy’s, Mylan and more

...effective Nov. 9. Chien was chief commercial officer at Krystal Biotech Inc. (NASDAQ:KRYS).Protein degradation newco Monte Rosa Therapeutics Inc....
...Bio Inc. (NASDAQ:GOSS). Danielle Golovin Boehringer Ingelheim Horizon Therapeutics plc GlaxoSmithKline plc Dr. Reddy's Laboratories Ltd. Mylan N.V. Rhythm Pharmaceuticals Inc. Silence Therapeutics plc Monte Rosa Therapeutics Inc. Relmada...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...as Bristol-Myers Squibb Co. (NYSE:BMY), C4 and Monte Rosa Therapeutics Inc....
...Inc. PolyProx Therapeutics Ltd. Cedilla Therapeutics Inc. Cullgen Inc. Frontier Medicines Corp. Monte Rosa Therapeutics Inc. Ranok...
BioCentury | Sep 25, 2020
Finance

Sept. 24 Quick Takes: AveXis vets steer Taysha to IPO; plus Exact Sciences, Monte Rosa, OBiO, Moderna, Immetas and more

...cap of more than $14 billion.Aisling leads $96M series B for Monte RosaProtein degradation company Monte Rosa Therapeutics Inc....
BioCentury | May 27, 2020
Emerging Company Profile

Versant’s Monte Rosa debuts with $32.5M, library of molecular glues for protein degradation

...by the field’s first drugs, thalidomide derivatives. Launched from Versant Ventures’ Swiss incubator lab Ridgeline, Monte Rosa Therapeutics Inc....
...degrons is ongoing at BMS following the pharma’s acquisition of Celgene in 2019. COMPANY PROFILE Monte Rosa Therapeutics Inc....
...Cereblon IKAROS (IKZF1; LYF1) - IKAROS family zinc finger 1 Karen Tkach Tuzman, Associate Editor protein degradation Monte Rosa Therapeutics Inc....
BioCentury | Feb 8, 2020
Tools & Techniques

Beyond PROTACs and the proteasome: broadening the TAC toolbox

...its chemoproteomics platform to find ligands to incorporate into targeted protein degraders, and stealth company Monte Rosa Therapeutics Inc....
Items per page:
1 - 7 of 7